Disease-free survival (DFS) according to the postremission therapy.

(A) Because of the poor outcome associated with the IDAC-1 group, DFS was significantly influenced by the postremission therapy (P = .03, by the log-rank test) (B). Overall, DFS was similar in patients from the CHEMO group (including HDAC-2, IDAC-2, and IDAC-1) as compared to those from the ALLO group (P = .55, by the log-rank test).